Cargando…

Conditionality of COVID-19 vaccine acceptance in European countries

The COVID-19 vaccine rollout has offered a powerful preventive measure to help control SARS-CoV-2 transmission. Nevertheless, long-standing public hesitation around vaccines heightened concerns that vaccine coverage would not achieve desired public health impacts, particularly in light of more conta...

Descripción completa

Detalles Bibliográficos
Autores principales: Heyerdahl, Leonardo W., Vray, Muriel, Lana, Benedetta, Tvardik, Nastassia, Gobat, Nina, Wanat, Marta, Tonkin-Crine, Sarah, Anthierens, Sibyl, Goossens, Herman, Giles-Vernick, Tamara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806150/
https://www.ncbi.nlm.nih.gov/pubmed/35125225
http://dx.doi.org/10.1016/j.vaccine.2022.01.054
_version_ 1784643380335083520
author Heyerdahl, Leonardo W.
Vray, Muriel
Lana, Benedetta
Tvardik, Nastassia
Gobat, Nina
Wanat, Marta
Tonkin-Crine, Sarah
Anthierens, Sibyl
Goossens, Herman
Giles-Vernick, Tamara
author_facet Heyerdahl, Leonardo W.
Vray, Muriel
Lana, Benedetta
Tvardik, Nastassia
Gobat, Nina
Wanat, Marta
Tonkin-Crine, Sarah
Anthierens, Sibyl
Goossens, Herman
Giles-Vernick, Tamara
author_sort Heyerdahl, Leonardo W.
collection PubMed
description The COVID-19 vaccine rollout has offered a powerful preventive measure to help control SARS-CoV-2 transmission. Nevertheless, long-standing public hesitation around vaccines heightened concerns that vaccine coverage would not achieve desired public health impacts, particularly in light of more contagious variants. This cross-sectional survey was conducted online just before the European vaccine rollout in December 2020 among 7000 respondents (aged 18–65) in Belgium, France, Germany, Italy, Spain, Sweden, and Ukraine. The survey included open text boxes for fuller explanation of responses. Overall, 56.9% of respondents would accept a COVID-19 vaccine, 19.0% would not, and 24.1% did not know or preferred not to say. By country, between 44% (France) and 66% (Italy) of respondents would accept a COVID-19 vaccine. Respondents expressed conditionality in open responses, voicing concerns about vaccine safety and mistrust of authorities. We highlight lessons learned about the dynamism of vaccine conditionality and persistence of safety concerns.
format Online
Article
Text
id pubmed-8806150
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Author(s). Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-88061502022-02-02 Conditionality of COVID-19 vaccine acceptance in European countries Heyerdahl, Leonardo W. Vray, Muriel Lana, Benedetta Tvardik, Nastassia Gobat, Nina Wanat, Marta Tonkin-Crine, Sarah Anthierens, Sibyl Goossens, Herman Giles-Vernick, Tamara Vaccine Short Communication The COVID-19 vaccine rollout has offered a powerful preventive measure to help control SARS-CoV-2 transmission. Nevertheless, long-standing public hesitation around vaccines heightened concerns that vaccine coverage would not achieve desired public health impacts, particularly in light of more contagious variants. This cross-sectional survey was conducted online just before the European vaccine rollout in December 2020 among 7000 respondents (aged 18–65) in Belgium, France, Germany, Italy, Spain, Sweden, and Ukraine. The survey included open text boxes for fuller explanation of responses. Overall, 56.9% of respondents would accept a COVID-19 vaccine, 19.0% would not, and 24.1% did not know or preferred not to say. By country, between 44% (France) and 66% (Italy) of respondents would accept a COVID-19 vaccine. Respondents expressed conditionality in open responses, voicing concerns about vaccine safety and mistrust of authorities. We highlight lessons learned about the dynamism of vaccine conditionality and persistence of safety concerns. The Author(s). Published by Elsevier Ltd. 2022-02-23 2022-02-01 /pmc/articles/PMC8806150/ /pubmed/35125225 http://dx.doi.org/10.1016/j.vaccine.2022.01.054 Text en © 2022 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Short Communication
Heyerdahl, Leonardo W.
Vray, Muriel
Lana, Benedetta
Tvardik, Nastassia
Gobat, Nina
Wanat, Marta
Tonkin-Crine, Sarah
Anthierens, Sibyl
Goossens, Herman
Giles-Vernick, Tamara
Conditionality of COVID-19 vaccine acceptance in European countries
title Conditionality of COVID-19 vaccine acceptance in European countries
title_full Conditionality of COVID-19 vaccine acceptance in European countries
title_fullStr Conditionality of COVID-19 vaccine acceptance in European countries
title_full_unstemmed Conditionality of COVID-19 vaccine acceptance in European countries
title_short Conditionality of COVID-19 vaccine acceptance in European countries
title_sort conditionality of covid-19 vaccine acceptance in european countries
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806150/
https://www.ncbi.nlm.nih.gov/pubmed/35125225
http://dx.doi.org/10.1016/j.vaccine.2022.01.054
work_keys_str_mv AT heyerdahlleonardow conditionalityofcovid19vaccineacceptanceineuropeancountries
AT vraymuriel conditionalityofcovid19vaccineacceptanceineuropeancountries
AT lanabenedetta conditionalityofcovid19vaccineacceptanceineuropeancountries
AT tvardiknastassia conditionalityofcovid19vaccineacceptanceineuropeancountries
AT gobatnina conditionalityofcovid19vaccineacceptanceineuropeancountries
AT wanatmarta conditionalityofcovid19vaccineacceptanceineuropeancountries
AT tonkincrinesarah conditionalityofcovid19vaccineacceptanceineuropeancountries
AT anthierenssibyl conditionalityofcovid19vaccineacceptanceineuropeancountries
AT goossensherman conditionalityofcovid19vaccineacceptanceineuropeancountries
AT gilesvernicktamara conditionalityofcovid19vaccineacceptanceineuropeancountries